Nektar Therapeutics Stock Performance
| NKTR Stock | USD 1.32 0.06 4.35% |
Nektar Therapeutics holds a performance score of 17 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of 2.17, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Nektar Therapeutics will likely underperform. Use Nektar Therapeutics maximum drawdown, as well as the relationship between the skewness and day typical price , to analyze future returns on Nektar Therapeutics.
Risk-Adjusted Performance
17 of 100
Weak | Strong |
Solid
Compared to the overall equity markets, risk-adjusted returns on investments in Nektar Therapeutics are ranked lower than 17 (%) of all global equities and portfolios over the last 90 days. Even with relatively weak basic indicators, Nektar Therapeutics reported solid returns over the last few months and may actually be approaching a breakup point. ...more
Last Split Factor 2:1 | Last Split Date 2000-08-23 |
1 | Sale by Mark Wilson of 7606 shares of Nektar Therapeutics | 02/22/2024 |
2 | Primecap Management Co. CA Sells 951,893 Shares of Nektar Therapeutics | 02/27/2024 |
3 | Nektar Therapeutics preliminary results from the TNBC cohort of the Ph12 PIVOT-02 study Transcript | 03/05/2024 |
4 | Research Analysts Offer Predictions for Nektar Therapeutics FY2026 Earnings | 03/06/2024 |
5 | Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune Inflammatory Disease Virtual Conference | 03/22/2024 |
6 | Heres Why You May Add Nektar Stock to Your Portfolio - Yahoo Movies UK | 04/01/2024 |
7 | Acquisition by Roy Whitfield of 20400 shares of Nektar Therapeutics at 3.47 subject to Rule 16b-3 | 04/02/2024 |
8 | Nektar Up 7.5 percent Since Last Earnings Report Can It Continue | 04/03/2024 |
9 | Nektar Network Unveiled to Elevate Ethereums Trust Layer and Combat Centralization | 04/11/2024 |
10 | Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer | 04/18/2024 |
11 | NK Cell Therapies Pipeline Report 2024 Insights on 80 Companies and 100 Pipeline Drugs, Including ALECSAT , NKTR-214Bempegaldesleukin , and Monalizumab | 04/26/2024 |
| Begin Period Cash Flow | 66.8 M |
Nektar |
Nektar Therapeutics Relative Risk vs. Return Landscape
If you would invest 56.00 in Nektar Therapeutics on January 29, 2024 and sell it today you would earn a total of 76.00 from holding Nektar Therapeutics or generate 135.71% return on investment over 90 days. Nektar Therapeutics is currently generating 1.5936% in daily expected returns and assumes 7.3239% risk (volatility on return distribution) over the 90 days horizon. In different words, 64% of stocks are less volatile than Nektar, and 69% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Nektar Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Nektar Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Nektar Therapeutics, and traders can use it to determine the average amount a Nektar Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.2176
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | NKTR | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 7.32 actual daily | 64 64% of assets are less volatile |
Expected Return
| 1.59 actual daily | 31 69% of assets have higher returns |
Risk-Adjusted Return
| 0.22 actual daily | 17 83% of assets perform better |
Based on monthly moving average Nektar Therapeutics is performing at about 17% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Nektar Therapeutics by adding it to a well-diversified portfolio.
Nektar Therapeutics Fundamentals Growth
Nektar Stock prices reflect investors' perceptions of the future prospects and financial health of Nektar Therapeutics, and Nektar Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Nektar Stock performance.
| Return On Equity | -1.11 | ||||
| Return On Asset | -0.15 | ||||
| Operating Margin | (1.28) % | ||||
| Current Valuation | 169.16 M | ||||
| Shares Outstanding | 183.62 M | ||||
| Price To Earning | 8.02 X | ||||
| Price To Book | 2.34 X | ||||
| Price To Sales | 3.40 X | ||||
| Revenue | 90.12 M | ||||
| Gross Profit | 70.42 M | ||||
| EBITDA | (129.61 M) | ||||
| Net Income | (276.06 M) | ||||
| Cash And Equivalents | 546.39 M | ||||
| Cash Per Share | 2.91 X | ||||
| Total Debt | 230.4 M | ||||
| Debt To Equity | 0.33 % | ||||
| Current Ratio | 7.14 X | ||||
| Book Value Per Share | 0.68 X | ||||
| Cash Flow From Operations | (192.61 M) | ||||
| Earnings Per Share | (1.45) X | ||||
| Market Capitalization | 242.38 M | ||||
| Total Asset | 398.03 M | ||||
| Retained Earnings | (3.48 B) | ||||
| Working Capital | 279.43 M | ||||
| Current Asset | 350.05 M | ||||
| Current Liabilities | 61.25 M | ||||
About Nektar Therapeutics Performance
To evaluate Nektar Therapeutics Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Nektar Therapeutics generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Nektar Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Nektar Therapeutics market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Nektar's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 160.38 | 141.06 | |
| Return On Tangible Assets | (0.69) | (0.66) | |
| Return On Capital Employed | (0.40) | (0.38) | |
| Return On Assets | (0.69) | (0.66) | |
| Return On Equity | (2.11) | (2.21) |
Things to note about Nektar Therapeutics performance evaluation
Checking the ongoing alerts about Nektar Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Nektar Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Nektar Therapeutics is way too risky over 90 days horizon | |
| Nektar Therapeutics may become a speculative penny stock | |
| Nektar Therapeutics appears to be risky and price may revert if volatility continues | |
| Nektar Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 90.12 M. Net Loss for the year was (276.06 M) with profit before overhead, payroll, taxes, and interest of 70.42 M. | |
| Nektar Therapeutics currently holds about 546.39 M in cash with (192.61 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.91, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 67.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: NK Cell Therapies Pipeline Report 2024 Insights on 80 Companies and 100 Pipeline Drugs, Including ALECSAT , NKTR-214Bempegaldesleukin , and Monalizumab |
- Analyzing Nektar Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Nektar Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Nektar Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Nektar Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Nektar Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Nektar Therapeutics' stock. These opinions can provide insight into Nektar Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nektar Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Nektar Stock, please use our How to Invest in Nektar Therapeutics guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Complementary Tools for Nektar Stock analysis
When running Nektar Therapeutics' price analysis, check to measure Nektar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nektar Therapeutics is operating at the current time. Most of Nektar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nektar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nektar Therapeutics' price. Additionally, you may evaluate how the addition of Nektar Therapeutics to your portfolios can decrease your overall portfolio volatility.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |
Is Nektar Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nektar Therapeutics. If investors know Nektar will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nektar Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.45) | Revenue Per Share 0.474 | Quarterly Revenue Growth 0.085 | Return On Assets (0.15) | Return On Equity (1.11) |
The market value of Nektar Therapeutics is measured differently than its book value, which is the value of Nektar that is recorded on the company's balance sheet. Investors also form their own opinion of Nektar Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Nektar Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nektar Therapeutics' market value can be influenced by many factors that don't directly affect Nektar Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nektar Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Nektar Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nektar Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.